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Response to β2-agonists differs between asthmatics and has been linked to subsequent adverse 
events, even death. Possible determinants include β2-adrenoceptor genotype at position 16, 
lung function, and airway hyperresponsiveness. Fluctuation analysis provides a simple 
parameter α measuring the complex correlation properties of day-to-day peak expiratory flow. 
We investigated whether α predicts clinical response to β2-agonist treatment, taking into 
account other conventional predictors. 
 
Analysis was performed on previously-published twice-daily peak expiratory flow 
measurements in 66 adult asthmatics over three six-month randomised order treatment 
periods – placebo, salbutamol and salmeterol. Multiple linear regression was used to 
determine the association between α during placebo period and response to treatment (change 
in number of days with symptoms), taking into account other predictors namely β2-
adrenoceptor genotype, lung function, its variability, and airway hyperresponsiveness. 
 
We found that α during placebo period considerably improved the prediction of response to 
salmeterol treatment, taking into account genotype, lung function or its variability, or airway 
hyperresponsiveness. 
 
We provide further evidence that response to β2-agonists is related to the time correlation 
properties of lung function in asthma. We conclude that fluctuation analysis of lung function 
offers a novel predictor to identify patients who may respond well or poorly to treatment.  
Abstract word count: 198/200 
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INTRODUCTION 
The β2-agonist controversy is based on substantial evidence relating β2-agonist use to adverse 
asthma outcomes, including mortality[1-5]. Responses to β2-agonists differ among 
individuals[2, 6]. This heterogeneity may partly be related to β2-adrenoceptor (ADRB2) 
genotypes[2, 6-12]. The homozygous Arg-16 polymorphism has been associated with poorer 
outcomes[7, 8], although findings are not entirely consistent[13, 14]. Additionally, airway 
hyperresponsiveness, lung function and its variability have been proposed to predict treatment 
response[15]. However, often only a weak relationship exists between these factors and 
treatment response, suggesting that conventional pathophysiological measurements are 
inadequate to predict the behaviour of complex diseases such as asthma[16, 17]. Therefore, a 
crucial target for investigation remains: to find new predictors which allow clinicians to 
identify patients who would or would not benefit from treatment. 
 
The complexities in asthma could be characterised in a novel way, by considering it as a 
dynamical disease[16, 18-23]. In this context, the likelihood of loss of asthma control may be 
better characterised by fluctuation analysis[24] applied to time series of daily variations in 
peak expiratory flow (PEF)[18]. The method yields a single parameter α, which quantifies the 
strength of long-range correlations present in the time series. The presence of long-range 
correlations means that PEF on any given day is dependent on its values on previous days 
even over longer time intervals[18], consistent with fractal behavior. Hence α can be thought 
of as a measure of complexity arising from the intrinsic control of the system producing the 
fluctuations, and likely influenced by external stimuli. Fluctuation analyses have been applied 
to heart rate variability[24], end-tidal oxygen and carbon dioxide concentrations[25], and tidal 
volume[25, 26]. Analysis of heart rate fluctuations have even been used to predict tachycardia 
following a myocardial infarction[27]. Using twice-daily PEF, we have reported that in a 
group of mild to moderate asthmatic adults in a randomised placebo-controlled three-way 
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crossover study[28], α tended to increase, and thus asthma control improved, during long-
term salmeterol treatment. In contrast, α significantly decreased during long-term salbutamol 
treatment[18]. Thus, α has value in characterising asthma control during treatment. 
 
In this study, we aimed to determine whether α measured in the absence of regular treatment, 
using data obtained during the placebo period (α(PL)), has value in predicting clinical 
response to long-term β2-agonist treatment. To answer this, we determined the association 
between α(PL) and changes in number of days with clinical symptoms during treatment, 
taking into account other important predictors of treatment response, namely ADRB2 




MATERIAL AND METHODS  
Study population and design 
This study was a retrospective analysis of a randomised, double-blind, double-dummy, 
crossover study, approved by the Otago and Canterbury ethics committees[28, 29]. Briefly, 
157 mild to moderate asthmatic adult subjects underwent a four-week run-in period involving 
assessment of spirometric lung function (FEV1) and airway responsiveness to methacholine 
(provocative concentration causing 20% fall in FEV1, PC20FEV1). This was followed by three 
six-month randomised treatment periods during which they received salmeterol 50 µg twice 
daily, salbutamol 400 µg four times daily, or lactose placebo, with intervening four-week 
placebo washout periods. Subjects maintained the same dosage of their inhaled 
corticosteroids, if applicable, for at least three months prior to and during the study, but were 
allowed on-demand rescue bronchodilators and emergency oral corticosteroids for 
exacerbations as appropriate.  
 
Patients were instructed to record their PEF and respiratory symptoms twice daily in a diary 
card. Symptoms recorded included day- and night-time chest tightness/wheeze/dyspnoea, 
cough, sputum production, exercise, and nocturnal wakening, rated on a 0 to 3 scale or a 
yes/no response where applicable. A composite asthma score taking into account symptoms, 
morning PEF, and rescue bronchodilator use was computed for each study day, ranging from 
0 for stable asthma to 4 for major exacerbation/medical emergency. Details of the asthma 
score calculation have been previously published[28].  
 
Of the 157 subjects in the database (80 of whom have had their fluctuation analysis data 
reported previously[18]), 66 were identified who had undergone genotyping for ADRB2 
position 16[29], lung function and airway hyperresponsivess testing, and for whom 




Fluctuation analysis was undertaken using custom-written software (Matlab, The Mathworks 
Inc, MA) as described previously[18]. The analysis was limited to PEF time series with 300 
data points for each treatment period, corresponding to the first 150 days of each treatment 
period, in order to standardise the data length across subjects. The time series was first 
integrated and then divided into non-overlapping windows of size n. The local trend in each 
window was removed by fitting and subtracting a regression line from the integrated data. 
The root-mean-square values of the detrended signal was calculated for a given window 
length n to yield the detrended fluctuation function, F(n). This calculation was then repeated 
for increasing n, and log F(n) was plotted against log n. Typically, F(n), a measure of the 
fluctuations, increases with n. A linear relation between log F(n) versus log n indicates the 
presence of scaling, which can be characterised by the slope α of the regression line fit.  
 
A PEF time series with α of 0.5 indicates a system that is not deterministic and prone to 
instabilities and exacerbations, whereas higher α values imply more deterministic behavior 
with stronger correlations present and hence are more likely to be the expression of stable and 
more predictable asthma control[18].  
 
Clinical outcome 
From the asthma score we derived the total number of symptom days, i.e. days when the 
asthma score was greater than zero within the same 150-day period which was used for 
fluctuation analysis. This outcome was chosen because, unlike total asthma score, it was not 
directly dependent on PEF. Our primary outcome was the difference in the number of 
symptom days between placebo and either the salbutamol or salmeterol treatment period (i.e., 
treatment – placebo). Thus, an increase (positive difference) in the number of symptom days 
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indicates deterioration in clinical condition, while a decrease (negative difference) indicates 
improvement. This outcome was less dependent on PEF than the asthma score (which 
included morning PEF as one dimension). 
 
Statistical analysis 
All statistical analyses were performed using Intercooled Stata 8.1 for Windows (Stata 
Corporation, College Station, Texas, USA). Multiple linear regression models were used to 
examine associations between potential predictors of interest and clinical outcome. To test the 
robustness of our findings, we performed two sensitivity analyses using slightly different 
statistical approaches. First, we looked at number of symptom days during treatment per se 
(i.e. not the difference from placebo) using a negative binomial regression model instead of 
linear regression, because the number of symptom days was not normally distributed but 
conformed to that expected from count or rate data. The more conventional Poisson 
regression (a special case of negative binomial regression) was not appropriate due to 
overdispersion, i.e. high variance compared to the mean. Second, we repeated the linear 
regression using differences in the mean asthma score between placebo and treatment as 
outcome, instead of differences in number of symptom days.   
 
A standard model was defined as the model in which adjustments were made for age, sex, 
treatment order, and number of symptom days during the placebo period. The possible effect 
of treatment order was adjusted for using the position of the relevant treatment period within 
the sequence of treatments. All continuous, i.e., non-categorical variables such as age and 
number of symptom days during the placebo period were centered to the mean. 
 
In a first, simple model, potential predictors of outcome were examined separately by adding 
each respective predictor to the standard model. Predictors of interest were: α(PL), ADRB2 
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genotype, lung function expressed as percentage of the predicted value for the subject[30] 
(%predPEF, %predFEV1), coefficient of variation of PEF (CVPEF), and airway 
hyperresponsiveness (PC20FEV1). To facilitate interpretation, these were stratified into low, 
medium and high tertiles, and comparison made with the lowest tertile as baseline, except for 
ADRB2 genotype, for which Gly/Gly genotype was used as the reference group. Thus, the 
coefficients reported are relative to the baseline group of subjects with low α(PL), low 
%predPEF, low %predFEV1, etc, with the baseline group effect represented by the constant 
term of the regression.  
 
Predictors which were found to be significantly associated with the outcome (p < 0.05) were 
then included into a fully-adjusted, multivariable model. Potential interaction between α(PL) 
and genotype within the multivariable model was tested for statistical significance using the 
F-test.  
 
To evaluate how well α(PL) predicted response to treatment relative to other parameters, we 
compared the adjusted R2 value of the standard model with models which included one or 
more of the predictors of interest (α(PL), ADRB2 genotype, %predPEF and CVPEF during 
the placebo period, and %predFEV1 and PC20FEV1 during run-in). Predictors were tested for 
significance using the F-test.  
 
Sensitivity to PEF quality control criteria 
For fluctuation analysis we used 300 PEF data points (150 days) with less than 3% missing 
data. We investigated the effect of relaxing this strict quality control criteria for inclusion of 
PEF time series into the study (by using shorter PEF series or allowing greater percentage of 






[18][29][18]Characteristics, spirometric lung function and airway hyperresponsiveness of the 
66 subjects obtained at run-in (FEV1, PC20FEV1), as well as potential predictors obtained 
during the placebo periods (α(PL), PEF, CVPEF), are summarised in Table 1. The mean (SD) 
values of the low, medium and high tertiles for the predictors are also shown. The three 
genotype groups were: homozygous Gly-16 (Gly/Gly), heterozygous (Gly/Arg) and 
homozygous Arg-16 (Arg/Arg). The genotype frequencies in the original population have 
been shown to be consistent with the Hardy-Weinberg equilibrium[29].  Clinical assessment 
parameters, i.e. the mean asthma score and number of symptom days during the placebo and 
treatment periods are given in Table 2.  
 
Association of α(PL) with clinical response to treatment 
 
For salmeterol, α(PL), %predPEF during placebo period and Arg/Arg genotype were 
significantly associated with response to treatment, both in the simple and the multivariable 
regression models (Table 3). The association between α(PL) and change in days with 
symptoms during salmeterol treatment became stronger in the multivariable model, with a 
mean improvement of -17.9 and -16.1 days with symptoms in individuals with medium and 
high α(PL), respectively, compared to those with low values. The association with genotype 
was not significant for Gly/Arg (p = 0.278) and was weak for Arg/Arg (p = 0.044). There was 




For salbutamol, the only predictor which was significantly associated with treatment outcome 
was %predPEF during placebo period, in both the simple and multivariable regression models 
(Table E1 in the online supplement).  
 
The changes in the number of symptom days in response to both salbutamol and salmeterol 
are illustrated in Figure 1.  With increasing α(PL) from the low, medium to high tertiles, 
relatively small change in symptom days is observed with salbutamol while progressively 
fewer symptom days are observed with salmeterol.  
 
Comparison of α(PL) with other predictors 
The R2 values of the standard regression model as well as models including one or more of 
the predictors of interest are shown in Table 4. Adding α(PL) to the model improved the 
goodness-of-fit from 0.563 in the standard model to 0.604. This was a similar improvement to 
adding %predPEF into the model, and better than for genotype or PC20FEV1. The goodness of 
fit increased to 0.662 when both α(PL) and %predPEF were included in the model, suggesting 
independent effects. 
  
Similar results were obtained with the two alternative statistical approaches (predicting 
number of symptom days per se using a negative binomial model, and predicting the 
difference in mean asthma score with a linear regression model). Results for genotype became 
weaker with asthma score as the outcome, but the associations with α(PL) and %predPEF 






In this study, we set out to determine the clinical utility of fluctuation analysis of PEF, 
specifically whether it helps to predict treatment outcome over and above conventionally-used 
predictors. We found that α(PL) was strongly and independently related to the change in 
clinical symptoms in response to salmeterol treatment. When coupled with %predPEF, α(PL) 
adds considerable predictive power to using CVPEF, %predFEV1, PC20FEV1 and ADRB2 
position 16 genotype.  
 
Interpretation of findings 
The strength of α as a predictor of treatment response lends further support to the idea that 
asthma is a complex dynamic disease[16, 18-21], well-characterised by a parameter which 
quantifies long-range correlations. In practical terms, if a patient has either a medium (or 
high) α during the placebo period, then that patient would likely have 18 (or 16) fewer days 
with symptoms during the 150 days of salmeterol treatment, i.e. 11% of treatment days. This 
compares with only 1% (from the constant term in the regression) of treatment days in a 
patient with a low α and %predPEF (based on data from Table 3). It is notable that a medium 
α appears to be as good as a high α, as the high tertile does not appear to result in further 
improvement compared to the medium tertile [18].  
 
Interestingly, if a patient had a high %predPEF during the placebo period, he would have 23 
(15%) more symptom days with treatment compared to low %predPEF, corrected for the 
number of symptom days during placebo. At first glance this seems counter-intuitive but 
could be due to a “ceiling” effect, whereby a person with low %predPEF has greater room for 
improvement with treatment and thus a very large negative change in symptom days, while a 
person with high %predPEF has only a modest negative change in symptom days.  
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There was a lack of predictive power of α(PL) for outcomes during salbutamol treatment. A 
possible explanation, consistent with our previous findings[18], is that the frequent short-term 
stimuli provided by salbutamol results in deterioration in asthma control independently of 
baseline α. As a consequence, the PEF pattern becomes irregular in time, which in turn results 
in a significant loss of predictive power. 
 
Combining α(PL) and %predPEF explained almost 10% of the total goodness-of-fit in 
modelling individual responses to treatment. This is especially beneficial as it does not require 
an additional measurement procedure for the patient, since the two are calculated from the 
same peak flow measurements. It is worth making the distinction between α and PEF here. A 
high α is not the only criterion for stability, since it is an indicator of time correlation 
properties of the PEF, as opposed to the properties of the PEF magnitude distribution. A 
patient with a high α, but low mean PEF or high CV in PEF, may still have poorly-controlled 
asthma, since these are independent properties of the daily PEF behaviour, both of which 
contribute independently to predicting whether a patient reamains stable or not[20].  
 
Significance of findings 
In our previous study, we found presence of long-range correlations in PEF, and that α was 
useful in characterising long-term treatment response[18]. Here, we show that it is also useful 
in predicting long-term treatment response, even when measured in the absence of such 
treatment (in this case during the placebo period). Also of note in our previous findings was 
the suggestion that there might be some “optimum” value of α, since any positive or negative 
deviation in α from a mean of 0.78 during the placebo period corresponded to a tendency for 
α to return to 0.78 with treatment[18]. In the present study, we see more evidence for this, 
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although in this case a plateau is more apparent: improvement in symptoms was optimally 
predicted when α was in the medium or high tertiles. Additionally, using multiple regression 
we were able to complement the value of α by taking into account other factors, notably 
%predPEF, and show that it compares favourably with other conventional predictors.  
 
Our results add value to the use of daily peak flow measurements in assessing and monitoring 
patients with asthma [31] by looking at its variability in a new way. Previously there has been 
doubt that regular measurements of peak flow add value in monitoring asthma given that they 
do not appear to be consistently related to current symptoms [32-34]. Zhang and coworkers 
have pointed out that multiple measurements of lung function over a length of time are a 
minimum criterion for being able to establish end points for asthma control[17]. With the 
advent of electronic peak flow monitoring and appropriate software for analyses, their 
predictive role in assessing asthma control may deserve renewed attention. Furthermore, a 
multi-dimensional approach to monitoring asthma, taking into account various factors and 
their relative contributions to asthma, is increasingly being advocated[16, 20, 32, 36]. The 
characterisation of time correlation properties of lung function complements this approach. 
 
Limitations and open questions 
Our study has a number of limitations. First, the numbers are small. One drawback of 
fluctuation analysis is that a large number of data points, e.g. 150 days, is necessary for the 
determination of long-range correlations. We have used very strict quality control criteria (see 
Appendix) to determine acceptability of individual PEF time series data into our study. This 
restricted the total number of eligible patients from the original study. We investigated 
relaxing these criteria, but found that as the length of the PEF series decreased, the association 
of α(PL) with outcome became less significant compared to %predPEF. This is not surprising 
given that the interpretation of long-range correlations becomes less important when the time 
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range of the data is decreased. Similarly as the percentage of missing data increased, a similar 
but less pronounced pattern emerged. Thus fluctuation analysis is to some extent dependent 
on the completeness of the data, and its use is limited to long-term monitoring of asthma. 
However, in such cases we provide an extra dimension of usefulness to data which would 
already be available[31]. Note that the actual time over which the data is collected is not the 
principal limitation of the method, rather it is the number of data points required to 
characterise the fluctuation dynamics. Analysis of variability from respiratory data collected 
with greater frequency and over shorter time-scales has been done in relation to asthma[19, 
23, 37], but the time scale over which interpretation of the results is made would likely have 
to be adjusted accordingly. It may be that fluctuations over short times scales can predict 
behaviour at longer time scales, which would be a great advantage, but this has yet to be 
shown. 
 
Second, corticosteroids and on-demand β2-agonist bronchodilators were permitted throughout 
the study.  There is evidence that concurrent use of corticosteroids mitigates the adverse effect 
of long-acting β2-agonists[38]. However, in our study the contribution of α(PL) and PEF to 
predicting better or worse response to salmeterol was apparent even in the presence of 
corticosteroid use. Third, we did not adjust for a past history of smoking, which could be a 
potential confounder given recent evidence for interaction between passive smoking and 
ADRB2 genotype[39]. However current and ex-smokers (>5 pack years) were excluded from 
the study. 
 
Finally, we calculated α using data obtained from the placebo period. Arguably, the run-in 
period would have been more suitable as it was prior to any treatment, unfortunately it was 
too short to allow adequate fluctuation analysis to be performed. However both periods would 
be comparable, given that during the run-in the subjects were taking placebo, there was a 
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washout of four weeks between treatment periods, and we have corrected for the possible 
effect of treatment order on the outcome in our regression analysis. Despite these limitations, 
what is clear from our study is that the relationship between α(PL) and symptom response to 





Having previously identified the utility of long-range correlations in daily lung function for 
characterising β2-agonist treatment responses, here we report their utility in predicting 
response to treatment. We found that fluctuation analysis of baseline lung function 
measurements was strongly associated with changes in symptoms with long-term treatment, 
in this instance using salmeterol. Baseline α, when coupled with mean daily peak flows, 
added considerably to the prediction of outcome compared to other conventional single 
measures of spirometric lung function, variability of lung function, airway 
hyperresponsiveness, as well as ADRB2 genotype, and contained information which seemed 
to be distinct and independent of these factors. This novel approach of looking at the time 
history of PEF recordings, distinct from studying its mean or variability, not only provides 
additional insight into asthma control, but also offers a potential new parameter to predict 
whether a patient will respond favourably or adversely to treatment in the future. This is 
particularly important in light of the potential detrimental response to β2-agonists. It also 
constitutes a step towards the multi-dimensional approach to asthma monitoring, which is 
increasingly valid in such a complex disease. 
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APPENDIX. Sensitivity to quality control criteria of PEF time series 
For our study and in previous work, we have used strict acceptability criteria to determine if a 
time series was to be included into the analysis. The criteria were as follows: at least 300 PEF 
data points (150 days) available, less than 3% missing data, and furthermore these two criteria 
had to be met in all treatment and placebo periods for a subject to be included into the study. 
Where there were missing data, they were replaced by the PEF value of the previous 
corresponding day/night, as detailed previously[18].  
 
We repeated the regression analyses of Tables 3 and 4, while comparing α(PL) calculated 
using the following criteria: using 300, 200 and 100 data points, and allowing less than 3%, 
5% and 10% missing data in the PEF time series. To allow comparison across different data 
lengths, the outcome (change in number of symptom days from placebo to treatment period) 
was calculated over the entire 150 day observation period regardless of data length used to 
calculate α(PL), but normalised to one year.  
 
We found that the association of α(PL) with outcome became less significant as the length of 
the PEF series decreased from 300 to 100 data points (from –14.2 days per observation 
period, p = 0.009 to –8.9 days per observation period, p = 0.096, both for the highest α(PL) 
tertile), as %predPEF during placebo period became more important. The association of 
α(PL) with outcome also became less significant as the percentage of missing data increased 
from 3% (from –14.2 days per observation period, p = 0.009 to -9.8 days per observation 
period, p = 0.058, both for the highest α(PL) tertile) to 10%, although the effect was 
marginally less pronounced than with the data length. However, α(PL) and %predPEF still 
yielded the greatest increase in model fit from the standard model, regardless of data length or 
amount of missing data. 
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Relaxing the criterion from 300 to 100 data points resulted in the percentage of acceptable 
subjects changing from 71% to only 72% out of the total subjects with otherwise complete 
data (n = 108). When relaxing the criterion from 3% to 10% missing data allowable, the 
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Table 1. Characteristics of the study population including β2-adrenoceptor (ADRB2) 
genotype, lung function and airway hyperresponsiveness parameters obtained during the run-
in period prior to treatment randomisation (FEV1 and PC20FEV1), and parameters calculated 
from peak expiratory flow during the placebo period (α, PEF, CVPEF). See text for full 
descriptions of parameters. 
 
Characteristics Summary (n = 66) 
 
   Age (years)* 
 
45 (19 to 64) 
 
   Sex (M:F) 
 
33:33 
   Height (cm)* 
 
170 (152 to 194) 
   ADRB2 genotype 
 
Gly/Gly: Gly/Arg: Arg/Arg  





Run-in Low Medium High 
   %predFEV1 (%) † 
 
57.4 (10.4) 77.7 (4.7) 95.0 (9.4) 
   PC20FEV1 (mg mL-1)‡ 
 
0.26  
(0.19 to 0.35) 
1.21  
(1.04 to 1.40) 
3.67  
(3.11 to 4.33) 
 
Placebo period    
   α † 
 
0.59 (0.06) 0.74 (0.03) 0.96 (0.15) 
   PEF (L min-1) † 
 
304 (34) 405 (22) 520 (49) 
   %predPEF (%) † 
 
58.1 (5.2) 75.4 (4.5) 91.9 (7.0) 










* Median with ranges shown 
† Mean with standard deviation shown 




Table 2. Asthma score and number of days with symptoms obtained during the placebo, 
salbutamol and salmeterol treatment periods (medians and interquartile ranges). 
 
n = 66 
 
Placebo  Salbutamol Salmeterol 
Mean asthma score *   
 
0.15 
 (0.05 to 0.33) 
 
0.15 
 (0.09 to 0.39) 
 
0.05 
 (0.01 to 0.13) 
Median number of days 
with symptoms † 
 
22 
 (7 to 46) 
22 
(12 to 56) 
8 
(2 to 19) 
 
Outcomes were calculated over an observation period of 150 days. Numbers in bold indicate 
statistical significance (Wilcoxon signed rank test, p<0.05), compared to placebo. 
* Mean over the observation period of a composite asthma score comprising symptoms, 
morning PEF, and rescue bronchodilator use computed for each study day, ranging from 0 for 
stable asthma to 4 for major exacerbation/medical emergency. See online supplement for 
more details. 
† Median over the observation period for the number of days on which a non-zero asthma 




Table 3. Association between patient characteristics at baseline and response to salmeterol 
treatment (defined as change in number of symptom days from the placebo period).  
  Simple model   Multivariable*  
Effect Coeff. 95% CI P value Coeff. 95% CI P value
α(PL) †       
     Medium -15.3 -27.4 to -3.1 0.015 -17.9 -29.4 to -6.4 0.003 
     High -15.4 -28.2 to -2.7 0.018 -16.1 -28.5 to -3.8 0.012 
ADRB2 genotype       
     Gly/Arg -2.8  -14.3 to 8.8 0.633 -5.6 -16.0 to 4.7 0.278 
     Arg/Arg -17.2 -32.9 to -1.4 0.034 -14.6 -28.9 to -0.4 0.044 
%predPEF during PL       
     Medium  11.6 -1.0 to 24.3 0.071 8.3 -3.3 to 19.9 0.158 
     High 17.6 4.1 to 31.1 0.012 22.9 10.4 to 35.4 0.001 
CVPEF during PL       
     Medium  -1.5 -14.8 to 11.7 0.815 - - - 
     High -11.2 -26. 9 to 4.8 0.158 - - - 
%predFEV1       
     Medium  7.7 -5.1 to 20.6 0.234 - - - 
     High  16.1 2.9 to 29.3 0.018 - - - 
PC20FEV1       
     Medium  2.6 -10.9 to 16.1 0.702 - - - 
     High  6.4 -7.0 to 19.9 0.343 - - - 
Constant ‡ - - - -1.5 -15.5 to 12.4 0.825 
 
Results derived from multiple linear regression. All models were adjusted for age, sex, 
sequence of treatment, and number of symptom days during placebo period (PL) by default. 
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All non-categorical variables such as age and number of symptom days during the placebo 
period were centred to the corresponding mean. Comparisons were made against having low 
α(PL), Gly/Gly genotype and low %predPEF, CVPEF during the placebo period, %predFEV1 
and PC20FEV1 during run-in period.  
* R2 for the fully-adjusted multivariable model was 0.677. Due to collinearity, only one lung 
function parameter was included in the multivariable model. 
† If a patient has either a medium (or high) α during the placebo period, then that patient 
would likely have 18 (or 16) fewer days with symptoms during the 150 days of salmeterol 
treatment, i.e. 11% of treatment days, compared to the placebo period. 
‡ A patient with Gly/Gly genotype, a low α and %predPEF during the placebo period will 
have a mean improvement in number of symptom days of 1.5 days (1%) during  the 150 days 
of salmeterol treatment compared to the placebo period.  
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Table 4. Comparison of goodness-of-fit between linear regression models with different 
potential predictors of the change in number of symptom days from the placebo period with 
salmeterol treatment.  
 
Potential predictor Adjusted R2 * P value † 
Standard model 0.563 - 
α(PL) 0.604 0.022 
ADRB2 genotype 0.582 0.102 
%predPEF during PL 0.599 0.030 
CVPEF during PL 0.565 0.328 
%predFEV1 0.590 0.059 
PC20FEV1 0.555 0.632 
α(PL) and %predPEF during PL 0.662 0.001 
Multivariable model (fully-adjusted) 0.677 0.001 
 
All models were adjusted for age, sex, sequence of treatment, and number of symptom days 
during placebo period (PL) by default. The predictors α(PL), %predPEF, CVPEF, 
%predFEV1 and PC20FEV1 were categorised into tertiles of low, medium and high values. For 
ADRB2 position 16 genotype, Gly/Gly was the reference group. 
* Note that each parameter was added to the model separately, i.e. the adjusted R2 values are 
not cumulative.  
† P values are shown for the F test, where the null hypothesis was that the relevant parameter 







Figure 1. Boxplots showing change in number of symptom days from placebo during 
treatment with salbutamol and salmeterol, in subjects with values of α during placebo (α(PL)) 
within the low, medium and high tertiles. The median is shown for each boxplot, with the box 
boundaries denoting the 25th and 75th percentiles, and the error bars denoting the 10th and 90th 
percentiles. Dots indicate outliers. A negative change indicates improvement of symptoms 
due to decreased number of symptom days with treatment compared to placebo. With 
increasing α(PL) from the low, medium to high tertiles, relatively little changes in symptom 
days are seen with salbutamol and progressively less symptom days for salmeterol. 
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